Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.
Metastatic Breast Cancer
DRUG: Ixabepilone
To assess the tumor response using RECIST Criteria to determine the best overall response and response rate, For a maximum of 9 3-week cycles or until unacceptable toxicity
To evaluate safety of BMS-247550 (AEs, SAEs, Deaths, treatment related AEs) using CTC Criteria, Every cycle|To evaluate the duration of achieved responses, For a maximum of 9 3-week cycles or until unacceptable toxicity|To evaluate time to progression (TTP), For a maximum of 9 3-week cycles or until unacceptable toxicity
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.